These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 29331748

  • 1. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
    Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.
    Eur J Cancer; 2018 Mar; 91():21-29. PubMed ID: 29331748
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
    Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.
    Ann Oncol; 2017 Feb 01; 28(2):368-376. PubMed ID: 27687304
    [Abstract] [Full Text] [Related]

  • 5. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
    Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S.
    Eur J Cancer; 2018 Dec 01; 105():88-102. PubMed ID: 30439628
    [Abstract] [Full Text] [Related]

  • 6. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.
    Lancet Haematol; 2019 Jan 01; 6(1):e48-e57. PubMed ID: 30528137
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O.
    Eur J Cancer; 2017 Sep 01; 82():34-44. PubMed ID: 28646772
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
    Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S.
    Eur J Cancer; 2018 Jun 01; 96():91-104. PubMed ID: 29698933
    [Abstract] [Full Text] [Related]

  • 11. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R.
    Eur J Cancer; 2019 Mar 01; 109():21-27. PubMed ID: 30682533
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
    Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A.
    Eur J Cancer; 2020 Apr 01; 129():71-79. PubMed ID: 32143106
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.
    Yoneshima Y, Tanaka K, Shiraishi Y, Hata K, Watanabe H, Harada T, Otsubo K, Iwama E, Inoue H, Masuda S, Nakanishi Y, Okamoto I.
    Lung Cancer; 2019 Apr 01; 130():5-9. PubMed ID: 30885351
    [Abstract] [Full Text] [Related]

  • 15. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N.
    BMC Cancer; 2019 Oct 21; 19(1):974. PubMed ID: 31638948
    [Abstract] [Full Text] [Related]

  • 16. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.
    Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D.
    Cancer Immunol Immunother; 2019 Jun 21; 68(6):917-926. PubMed ID: 30877325
    [Abstract] [Full Text] [Related]

  • 17. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H, Hayashi T, Takigami K, Imaizumi K, Shiroki R, Ohmiya N, Sugiura K, Kawada K, Sawaki A, Maeda K, Ando Y, Uyama I.
    BMC Cancer; 2020 Jul 14; 20(1):656. PubMed ID: 32664888
    [Abstract] [Full Text] [Related]

  • 18. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC, German Dermatooncology Group (DeCOG).
    Eur J Cancer; 2017 Apr 14; 75():24-32. PubMed ID: 28214654
    [Abstract] [Full Text] [Related]

  • 19. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
    Narváez J, Juarez-López P, LLuch J, Narváez JA, Palmero R, García Del Muro X, Nolla JM, Domingo-Domenech E.
    Autoimmun Rev; 2018 Oct 14; 17(10):1040-1045. PubMed ID: 30103042
    [Abstract] [Full Text] [Related]

  • 20. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR.
    Ann Oncol; 2017 Oct 01; 28(10):2377-2385. PubMed ID: 28945858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.